Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

The study randomised 592 patients to receive Keytruda (200 mg fixed dose every three weeks) or paclitaxel on days one, eight, and 15 of each 28-day cycle. The study was designed to first evaluate ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

The study is a placebo-controlled, double-blind one examining setanaxib, a NOX enzyme inhibitor, 800mg twice daily in conjunction with Merck's (MRK) Keytruda pembrolizumab 200mg IV, given every ...

The trial enrolled 810 patients who were randomized (1:1) to receive either: Keytruda (200 mg intravenously [IV]) every three weeks (Q3W) plus paclitaxel (175 mg/m 2 IV) and carboplatin (Area Under ...

Merck has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial evaluating KEYTRUDA (pembrolizumab) plus trastuzumab and chemotherapy for the treatment of human ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar potential: It holds a first-mover advantage in one of the largest cancer indications of non-small cell ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...